HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.

Slides:



Advertisements
Similar presentations
Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
Advertisements

PRIMIS Third National Conference Tuesday 1 April 2003 Birmingham HIP for CHD Jane Matthews Practice Nurse Dr. Dai Evans PRIMIS Regional Clinical Adviser.
Long Distance Titration of Heart Failure Medications by Telephone Calls Anne E. Steckler, RN, Heba Wassif, MD, Kalkidan Bishu, MD, Gardar Sigurdsson, MD,
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.
National Service Frameworks Dr Stephen Newell February 2002.
Practical Tips in β-blocker Therapy in CHF β-blocker Therapy in CHF CMCC 11 th 11 th September 2009 Rungsrit Kanjanavanit MD. Cardiovascular Div. Dept.
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
1 Heart Failure William Chavey, MD, MS Associate Professor Department of Family Medicine University of Michigan.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.
analysis from the SHIFT study
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
Dr. Jon Salisbury Visiting Physician Services A Member of VNA Health Group No Disclosures May 14, :40PM – 2:00PM ©AAHCM.
Management of Chronic Heart Failure SIGN 95
Procoralan plus beta-blockers as first-step therapy in heart failure?
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
Heart Failure and Qof Quiz Justin Walker October 2010.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
Population Impact Measures (PIM)
Modern Management of heart Failure Dr Amanda Varnava Consultant Cardiologist Watford & St Mary’s Hospitals.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Indication:  Suspected Heart Failure With abnormal ECG or Intermediate BNP ( ) BNP:  Asymptomatic Murmur  Asymptomatic Cardiomegaly On CXR Direct.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
HEART FAILURE Prevalence increasing in our ageing population Incidence doubles with each decade between 40 and 80 At any age more common in men than women.
L References Application to Clinical Practice The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have cooperatively.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
NICE Guideline Synopsis. Definitions Stage 1 Hypertension Clinic BP 140/90 or higher And ABPM Daytime average/HBPM 135/85 or higher.
Management of Stable Angina SIGN 96
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
Primary care team meeting Hypertension Dr Som Desilva.
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
Camm J, et al. On Behalf of The SHIFT Gothenburg, Cardiac safety of selective heart rate reduction with Ivabradine in chronic heart failure. Poster, Heart.
Jennifer Bell British Heart Foundation Heart Failure Nurse Specialist.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Long Term Conditions Strategy There are 3 key aims to our improvement strategy: WHCCG has already achieved: – Commissioned Diabetes education through the.
CURRENT APPROACH TO THE TREATMENT OF CONGESTIVE HEART FAILURE.
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Eric J Robinson, M.D. Cardiologist April 25, 2015
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Prescribing in cardiovascular disease By Jole Hannan Medicines Optimisation Pharmacist.
Atrial Fibrillation: An old age problem PCCS Village Hotel 18 th May 2011.
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
Ridha Chakeer MD PGY3. Objectives: Approximately 5.2 million Americans are affected  accounts for more than 3 million outpatient visits to primary care.
Chronic heart failure By Vishal Patel GPVTS1.
Guideline: Chronic Heart Failure
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS
Ivabradine – A new option for Heart Failure Patients
Life after a Cardiovascular Event
CLINICAL DILEMMAS IN HEART FAILURE:
EMPHASIS-HF Extended Follow-up
Heart Rate, HF Admissions, and Readmissions
Section III: Neurohormonal strategies in heart failure
Section III: Neurohormonal strategies in heart failure
Section III: Neurohormonal strategies in heart failure
Basic troubleshooting for CRTs
NICE 2014 Check pulse in patients presenting with:
Presentation transcript:

HEART FAILURE

Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF 7. Lifestyle 8. Ivabradine 9. Monitoring

Diagnosis 1. ECG 2. BNP 3. CXR – for possible alternative diagnoses (together with blood tests and spirometry) 4. Echo

Drug therapy 1. ACE-I (or ARB if not tolerated). Titrate to evidence based dose – practically speaking this is usually the maximum dose. 2. Bisoprolol, carvedilol (or nebivolol for those over 70). A 20,000 patient (23 trial) meta analysis found 18% reduction in risk of death for every 5 bpm reduction in resting HR. No correlation between dose and death, ie higher doses are not better at reducing deaths than lower doses. The study strongly suggests reducing pulse is more important than dose. In sinus rhythm aim for 60 bpm. If resting pulse falls to < 50, halve the B blocker dose. In HF + AF keep HR > 70. Aim for 73 – 82 bpm. ?Prevents bradyarhythmias at night.

Drug therapy (cont) 3. Aldosterone antagonist. Spironolactone or eplerenone. Used to be recommended in NYHA III – IV if EF =/<35%. New evidence – use in NYHA II – IV (with EF =/<35%). 4. Aspirin and statin if CVD. 5. With AF & HF, if pulse not reduced to 73 – 82 bpm by B blocker, then add digoxin. 6. Ivabradine – specialist use only – not if any risk of AF.

Exercise and Lifestyle NICE: “Offer a supervised group exercise- based rehabilitation programme designed for patients with Heart Failure. Ensure the patient is stable and does not have a condition or device that would preclude the programme. …psychological and educational component.” Smoking, alcohol, sexual activity, imms.

Monitoring 1. Functional capacity, fluid status, rhythm, cognitive and nutritional status 2. Drugs 3. U&Es and eGFR. When starting aldosterone antagonist check U&Es 7 – 14 days later, with each dose change, and eventually at the very least every 6 months. Amiodarone needs 6 monthly TFTs & LFTs. Initially monitor patient’s clinical condition at short intervals (days to 2 wk) if condition / drugs change. Otherwise monitor at least 6 monthly.

4 Questions 1. Diagnosis. Primary Care – Can take several wks from decision for echo to results. Echos on ICE? Secondary Care – Should all patients with heart failure diagnosis have an echo while in patient. Need to know if heart failure symptoms or actual LVSD. If not possible, then ?hospital BNP screen followed by echo if positive.

4 Questions 2. Titrating B blockers Aim for pulse of 60 bpm, not dose of B blocker. 72 – 83 bpm in AF.

4 Questions 3. Blood monitoring U&Es after initiation and after every dose change of ACE-I / ARB / spironolactone. BNF: Thereafter minimum 6 monthly U&Es Also 6 monthly TFTs and LFTs if on amiodarone

4 Questions 4. Frequency of patient clinical monitoring 6 monthly monitoring when stable.(NICE) ?Alternating between practice nurse and GP.